Increased risk of fracture among breast cancer patients: a nationwide retrospective cohort study
- 7 February 2026
- journal article
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 20 (S2) , 1503-1514
Abstract
Breast cancer treatments contribute to bone loss and increase fracture risk, with effects varying by age and menopausal status. Previous studies lacked comparisons with the general population and analyses by treatment and age groups. This study evaluated fracture risk in breast cancer patients compared to a matched control group, considering risk factors, age, and treatments. This retrospective cohort study using the Korean National Health Insurance System database included 104,177 breast cancer patients and 312,531 matched controls. Fracture incidences (any, vertebral, hip, and other) by age and treatment type was assessed using Fine-Gray competing risk models. During the mean follow-up of 7.21 years after breast cancer diagnosis, breast cancer patients aged 50 years and younger had a higher risk of any fracture (sub-distribution hazard ratio [sHR], 1.33; 95% confidence interval [95% CI], 1.24-1.42) and vertebral fracture (sHR, 1.33; 95% CI, 1.13-1.56) compared to the matched control group. Patients aged 65 years and older had a lower risk of any fracture (sHR, 0.91; 95% CI 0.84-0.98) and vertebral fracture (sHR, 0.83; 95% CI, 0.73-0.93). Compared to patients without specified treatments, those who received anthracycline (sHR, 1.21; 95% CI, 1.15-1.28) and aromatase inhibitors (sHR, 1.16; 95% CI, 1.09-1.23) had an increased risk of fracture; and those who were given tamoxifen had a decreased risk (sHR, 0.92; 95% CI, 0.86-0.98). Breast cancer patients had slightly higher fracture risk, primarily in younger patients. Emphasizing osteoporosis prevention and treatment, especially in younger populations or those who have received treatments associated with an increased risk of fracture, is necessary to reduce fracture risk.Keywords
Funding Information
- Institution of Quality of Life in Cancer funded by Samsung Fire & Marine Insurance
This publication has 46 references indexed in Scilit:
- Fracture Risk in Older, Long‐Term Survivors of Early‐Stage Breast CancerJournal of the American Geriatrics Society, 2013
- Aromatase inhibitor-induced arthralgia: a reviewAnnals of Oncology, 2013
- The role of osteocyte apoptosis in cancer chemotherapy‐induced bone lossJournal of Cellular Physiology, 2011
- The incidence and residual lifetime risk of osteoporosis-related fractures in KoreaJournal of Bone and Mineral Metabolism, 2011
- Variation in risk factors for fractures at different sitesCurrent Osteoporosis Reports, 2009
- Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230Journal of Clinical Oncology, 2008
- Aromatase Inhibitors and Bone Health in Women With Breast CancerJournal of Clinical Oncology, 2006
- Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual StatusJournal of Clinical Oncology, 2006
- Fracture Risk Among Breast Cancer SurvivorsArchives of internal medicine (1960), 2005
- Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model.Journal of Bone and Joint Surgery, 1984